Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to "Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction".
Inghardt T, Antonsson T, Ericsson C, Hovdal D, Johannesson P, Johansson C, Jurva U, Kajanus J, Kull B, Michaëlsson E, Pettersen A, Sjögren T, Sörensen H, Westerlund K, Lindstedt EL. Inghardt T, et al. Among authors: lindstedt el. J Med Chem. 2022 Oct 13;65(19):13482. doi: 10.1021/acs.jmedchem.2c01533. Epub 2022 Oct 3. J Med Chem. 2022. PMID: 36190771 Free PMC article. No abstract available.
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
Nelander K, Lagerstrom-Fermer M, Amilon C, Michaëlsson E, Heijer M, Kjaer M, Russell M, Han D, Lindstedt EL, Whatling C, Gan LM, Ericsson H. Nelander K, et al. Among authors: lindstedt el. Clin Transl Sci. 2021 May;14(3):812-819. doi: 10.1111/cts.12859. Epub 2021 May 2. Clin Transl Sci. 2021. PMID: 32770730 Free PMC article. Clinical Trial.
Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.
Inghardt T, Antonsson T, Ericsson C, Hovdal D, Johannesson P, Johansson C, Jurva U, Kajanus J, Kull B, Michaëlsson E, Pettersen A, Sjögren T, Sörensen H, Westerlund K, Lindstedt EL. Inghardt T, et al. Among authors: lindstedt el. J Med Chem. 2022 Sep 8;65(17):11485-11496. doi: 10.1021/acs.jmedchem.1c02141. Epub 2022 Aug 25. J Med Chem. 2022. PMID: 36005476 Free PMC article.
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Gan LM, Lagerström-Fermér M, Ericsson H, Nelander K, Lindstedt EL, Michaëlsson E, Kjaer M, Heijer M, Whatling C, Fuhr R. Gan LM, et al. Among authors: lindstedt el. Br J Clin Pharmacol. 2019 Apr;85(4):762-770. doi: 10.1111/bcp.13855. Epub 2019 Feb 18. Br J Clin Pharmacol. 2019. PMID: 30618054 Free PMC article. Clinical Trial.
Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans.
Bhattacharya C, Sandinge AS, Bragg RA, Heijer M, Yan J, Andersson LC, Jurva U, Pelay-Gimeno M, Vaes WHJ, de Ligt RAF, Gränfors M, Amilon C, Lindstedt EL, Menakuru SR, Garkaviy P, Weidolf L, Gopaul VS. Bhattacharya C, et al. Among authors: lindstedt el. Drug Metab Dispos. 2023 Apr;51(4):451-463. doi: 10.1124/dmd.122.001100. Epub 2023 Jan 13. Drug Metab Dispos. 2023. PMID: 36639243
Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque.
Rashid I, Maghzal GJ, Chen YC, Cheng D, Talib J, Newington D, Ren M, Vajandar SK, Searle A, Maluenda A, Lindstedt EL, Jabbour A, Kettle AJ, Bongers A, Power C, Michaëlsson E, Peter K, Stocker R. Rashid I, et al. Among authors: lindstedt el. Eur Heart J. 2018 Sep 14;39(35):3301-3310. doi: 10.1093/eurheartj/ehy419. Eur Heart J. 2018. PMID: 30219874
Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.
Pettersen D, Broddefalk J, Emtenäs H, Hayes MA, Lemurell M, Swanson M, Ulander J, Whatling C, Amilon C, Ericsson H, Westin Eriksson A, Granberg K, Plowright AT, Shamovsky I, Dellsèn A, Sundqvist M, Någård M, Lindstedt EL. Pettersen D, et al. Among authors: lindstedt el. J Med Chem. 2019 May 9;62(9):4312-4324. doi: 10.1021/acs.jmedchem.8b02004. Epub 2019 Mar 26. J Med Chem. 2019. PMID: 30869888
Inhibition of MPO (Myeloperoxidase) Attenuates Endothelial Dysfunction in Mouse Models of Vascular Inflammation and Atherosclerosis.
Cheng D, Talib J, Stanley CP, Rashid I, Michaëlsson E, Lindstedt EL, Croft KD, Kettle AJ, Maghzal GJ, Stocker R. Cheng D, et al. Among authors: lindstedt el. Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1448-1457. doi: 10.1161/ATVBAHA.119.312725. Epub 2019 May 2. Arterioscler Thromb Vasc Biol. 2019. PMID: 31043077 Free article.
20 results